Clinical Trial Update: Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755) [Phase 3]

View source ↗

Summary

This phase 3 trial evaluated safety and efficacy of Boceprevir with Peginterferon alfa-2a and Ribavirin in IL-28B CC allele-positive chronic hepatitis C genotyp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Boceprevir (boceprevir)
• Peginterferon alfa-2a (peginterferon alfa-2a)
• Ribavirin (ribavirin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C, Chronic | Phase 3 | Status: COMPLETED | Results posted: 2016-05-30